The Discounted Cash Flow (DCF) valuation of Surface Oncology Inc (SURF) is (574.97) USD. With the latest stock price at 1.07 USD, the upside of Surface Oncology Inc based on DCF is -53835.4%.
Based on the latest price of 1.07 USD and our DCF valuation, Surface Oncology Inc (SURF) is a sell. selling SURF stocks now will result in a potential gain of 53835.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.6% - 8.3% | 7.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (2,876.44) - (320.55) | (574.97) |
| Upside | -268926.6% - -30057.6% | -53835.4% |